Drug maker Lupin has appointed Alok Sonig as CEO US Generics and Global Head Generics R&D & Biosimilars.
Sonig will report to Vinita Gupta and Nilesh Gupta Managing Director, Lupin.
He will be overall incharge of the US Generics business, including R&D activities in India and the US. Sonig will also be responsible for Lupin’s global biosimilars business.
Prior to this assignment, he worked as CEO of Developed Markets (US, Canada, Europe and Japan) at Dr Reddy’s Laboratories.
Before his stint at Dr Reddy’s Laboratories.,Sonig spent nearly 15 years at Bristol-Myers Squibb, where he held several senior positions.
“His global experience, strategic perspective, and operational focus will help accelerate our team’s efforts to strengthen and evolve our US generics business as we execute on near-term growth opportunities and navigate new platforms in complex generics and biosimilars,” Lupin CEO Vinita Gupta said in a statement.